HPV-16 E6 + HPV-18 E6 Antibody from BIORBYT LTD.
Search, find, compare suppliers for anti-HPV-16 E6 + HPV-18 E6 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | HPV-16 E6 + HPV-18 E6 |
| Clone | HPV16/1295 + HPV18/1297 |
| Host Species | Mouse |
| Reactive Species | n/a |
| Isotype | IgG1, kappa |
| Format | Protein G purified |
| Size | 20 ug, 100 ug |
| Concentration | n/a |
| Applications | ELISA |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Human papilloma viruses (HPVs) can be classified as either high risk or low risk according to their association with cancer. HPV16 and HPV18 are the most common of the high risk group while HPV6 and HPV11 are among the low risk types. Approximately 90% of cervical cancers contain HPV DNA of the high risk types. Mutational analysis has shown that the E6 and E7 genes of the high risk HPVs are necessary and sufficient for HPV transforming function. The specific interactions of the E6 and E7 proteins with p53 and pRB, respectively, correlate with HPV high and low risk classifications. The high risk HPV E7 proteins bind to pRB with a higher affinity than do the low risk HPV proteins, and only the high risk HPV E6 proteins form detectable complexes with p53 in vitro. |
| Immunogen | HPV18 E6-β-galactosidase fusion protein was used as the immunogen for this HPV-16 E6 + HPV-18 E6 antibody cocktail. |
| Other Names | n/a |
| Gene, Accession # | n/a |
| Catalog # | orb640128 |
| Price | $405 |
| Order / More Info | HPV-16 E6 + HPV-18 E6 Antibody from BIORBYT LTD. |
| Product Specific References | n/a |
BIORBYT LTD.
BIORBYT LTD.
7 Signet Court
Swann Road
Cambridge, CB5 8LA U.K.
P: +44 (0)1223 859 353
F: +44(0)1223 280 240
info@biorbyt.com
http://www.biorbyt.com
U.S. OFFICE
Biorbyt LLC
1100 Corporate Square Drive
Helix Center, Suite 221
St Louis, MO 63132
Email: info@biorbyt.com
Phone: +1 (415) 906-5211
Fax: +1 (415) 651-8558
Profile of BIORBYT LTD.
Return to Antibodies